Cost Effectiveness and Resource Allocation

Table 3 Results of scenario analyses at 1 years, 3 years, 5 years, 7 years of time horizon

From: Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis

Time horizon	TPC		SG		Incremental		ICER*($/QALM)
Time horizon	QALM	Cost	QALM	Cost	QALM	Cost	ICER*($/QALM)
1 year	5.66	4950	7.74	160,212	2.08	155,262	74,487
3 years	7.09	6407	11.77	224,631	4.68	218,224	46,648
5 years	7.12	6441	12.24	236,064	5.12	229,623	44,849
7 years	7.12	6442	12.29	237,683	5.16	231,241	44,795

^*Compared to TPC at a willing-to-pay of $3188/QALM in China.
Note: SG, Sacituzumab govitecan; TPC, single-agent treatment of physician’s choice; ICER, incremental cost-effectiveness ratio; QALM, quality adjusted life month.

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com